Therapeutic ultrasound developer Mirabilis Medica of Seattle reported that it has raised $10.5 million in an extension to its series A financing round. The funding will be used to continue developing and testing its image-guided high intensity focused ultrasound (HIFU) system for treatment of gynecological diseases.
Mirabilis’ technology is designed to allow a physician to destroy pathological tissue inside the body without damage to intervening tissue, and to monitor effects with real-time ultrasound imaging. While this approach could address a variety of conditions, Mirabilis said it will initially target its utilization for the treatment of uterine fibroids.
The series A extension was led by Arboretum Ventures of Ann Arbor Mich., and included Split Rock Partners, Dow Venture Capital, and an individual investor, according to the company.